The 4th Bioequivalence Summit 2017 covers topics such as:
- Advances in FDA regulations and requirements for ANDAs and biosimilars
- Innovative testing and modeling procedures that cut cost and provide more accurate results
- Legal challenges from originator drug companies that impact the development of biosimilars
- Highly demanded alternative delivery methods, such as long-acting injectables and topical applications
- The latest in current drug development issues, such as oncology and abuse-detterant innovation
The 4th Bioequivalence Summit 2017 brings together attendees with responsibilities in:
- Pharmaceutics/Biopharmaceutics
- Pharmacokinetics/Pharmacodynamics/Drug Metabolism/PKDM
- Drug Delivery
- Drug Discovery
- Formulation
- Preclinical Research
- Biostatistics
- Preformulation
- Life Cycle Management
